BR112023020900A2 - Compostos tetracíclicos para tratamento de distúrbios cerebrais - Google Patents

Compostos tetracíclicos para tratamento de distúrbios cerebrais

Info

Publication number
BR112023020900A2
BR112023020900A2 BR112023020900A BR112023020900A BR112023020900A2 BR 112023020900 A2 BR112023020900 A2 BR 112023020900A2 BR 112023020900 A BR112023020900 A BR 112023020900A BR 112023020900 A BR112023020900 A BR 112023020900A BR 112023020900 A2 BR112023020900 A2 BR 112023020900A2
Authority
BR
Brazil
Prior art keywords
brain disorders
treatment
compounds
tetracyclic compounds
tetracyclic
Prior art date
Application number
BR112023020900A
Other languages
English (en)
Inventor
E Olson David
R Tuck Jeremy
E Dunlap Lee
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR112023020900A2 publication Critical patent/BR112023020900A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

compostos tetracíclicos para tratamento de distúrbios cerebrais. a presente invenção refere-se a compostos heterocíclicos tetracíclicos que podem ser úteis para métodos de tratamento de uma doença ou para aumentar a plasticidade neural. os compostos também podem ser úteis para aumentar a densidade da espinha dendrítica.
BR112023020900A 2021-04-13 2022-04-13 Compostos tetracíclicos para tratamento de distúrbios cerebrais BR112023020900A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163174266P 2021-04-13 2021-04-13
PCT/US2022/024626 WO2022221415A2 (en) 2021-04-13 2022-04-13 Tetracyclic compounds for treating brain disorders

Publications (1)

Publication Number Publication Date
BR112023020900A2 true BR112023020900A2 (pt) 2023-12-12

Family

ID=83641012

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020900A BR112023020900A2 (pt) 2021-04-13 2022-04-13 Compostos tetracíclicos para tratamento de distúrbios cerebrais

Country Status (9)

Country Link
EP (1) EP4323359A2 (pt)
JP (1) JP2024515614A (pt)
KR (1) KR20230170053A (pt)
CN (1) CN117337289A (pt)
AU (1) AU2022258453A1 (pt)
BR (1) BR112023020900A2 (pt)
CA (1) CA3214953A1 (pt)
IL (1) IL307607A (pt)
WO (1) WO2022221415A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023115060A1 (en) * 2021-12-17 2023-06-22 The Regents Of The University Of California Psychoplastogens for treating hearing-related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT61548A (en) * 1990-08-27 1993-01-28 Sandoz Ag Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds
US5843682A (en) * 1995-11-20 1998-12-01 Boehringer Mannheim Corporation N-1-carboxyalkyl derivatives of LSD
EP1399445B9 (en) * 2000-12-20 2010-07-21 Bristol-Myers Squibb Company Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
WO2011103485A1 (en) * 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
AU2020228289A1 (en) * 2019-02-27 2021-09-09 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders

Also Published As

Publication number Publication date
JP2024515614A (ja) 2024-04-10
AU2022258453A1 (en) 2023-10-19
IL307607A (en) 2023-12-01
EP4323359A2 (en) 2024-02-21
WO2022221415A2 (en) 2022-10-20
CN117337289A (zh) 2024-01-02
CA3214953A1 (en) 2022-10-20
KR20230170053A (ko) 2023-12-18
WO2022221415A3 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
BR112021016650A2 (pt) Indóis substituídos por n e outros heterociclos para o tratamento de distúrbios cerebrais
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
EA201591614A1 (ru) Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения
BRPI0606902A2 (pt) composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica
UY39413A (es) Compuestos inhibidores de metaloenzimas
MA51524A (fr) Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
ECSP21080096A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra
BR112018014675A2 (pt) novos derivados de cianoindolina substituída como inibidores de nik
ECSP19021843A (es) Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades
BR112023020900A2 (pt) Compostos tetracíclicos para tratamento de distúrbios cerebrais
MX2020014303A (es) Inhibición de la proteína de union a creb (cbp).
MX2022011518A (es) Metodos para tratar deambulacion asociada a proteinopatia.
EA200900330A1 (ru) Аналоги 2-феноксипиримидинона
BR112017025263A2 (pt) método para o tratamento de doença neurológica
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
BR112022013554A2 (pt) Métodos para tratar distúrbios do pênfigo
BR112022021957A2 (pt) Imidazopirimidinas como moduladores de il -17
EA202092557A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОБЕНЗОФУРО[2,3-c]ПИРИДИНА И БЕТА-КАРБОЛИНА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ-БЕЛКА
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
WO2009155069A8 (en) Compositions and methods for treating psychiatric and neurodegenerative disorders
BR112018014525A2 (pt) compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств